CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

The prognosis of adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal even at this day and age. With salvage chemotherapy, only 29% (range 18 to 44%) of the patients with R/R...

Source: Journal of Hematology and Oncology - March 15, 2018 Category: Hematology Authors: Li-Na Zhang, Yongping Song and Delong Liu Tags: Research highlight Source Type: research